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MALIGNANT cells have been found in the bone marrow by many workers
but have usually been considered to occur only in cases of advanced malignancy,
andparticularly inthose inwhom thereisradiological evidence ofbone metastases,
(Stoger, 1941; Franke, 1942). In consequence sternal puncture has been only
rarely advocated as a diagnostic procedure in malignant disease.
Recent advances in surgery and anaesthetics and the development of new
techniques in radiotherapy and chemotherapy have made it important to assess
patients who have a restricted primary growth from those with metastases.
Sternal marrow examination by aspiration is now a simple procedure which may
be undertaken without fear on out-patients and, in consequence, it was considered
to be a possible method for searching for secondary spread.
Although Reich in 1935 reported the finding ofcarcinoma cells in bone marrow
aspiration in one patient the first large study was that ofRohr and Hegglin (1936)
who in a series of patients with advanced malignant disease found 10 positive
aspirations among 74 examined. Since this time many reports have appeared in
the literature of the finding of malignant cells. These findings have however
been largely made on patients with advanced disease and of the 338 positive
marrows reported in the papers only 40 were found in patients with negative
radiological findings (Pillers, 1955).
Leitner (1949) has reviewed the main papers relating to this subject. In
consequence further review here seems unnecessary. The present investigation was
undertaken to find answers to the following problems.
1. What are the characteristics feature ofmalignant cells in the marrow
and how may they be distinguished from other cells seen only rarely in
marrow punctures.
2. Whether it is possible to find tumour cells in the sternal marrow in
patients with clinically localised malignant tumours.
3. Whether there are any characteristic changes detectable in the bone
marrow with malignant spread other than the finding oftumour cells.
4. To assess the value of sternal marrow examination in assessing the
prognosis and deciding on the form of treatment to be given to patients
with malignant disease.
MATERIAL AND METHODS
A group of patients was selected who were attending the Radiotherapeutic
DepartmentofAddenbrooke's Hospitalforroutinetreatment,togetherwithpatients
undergoing bronchoscopy at Papworth Hospital for suspected carcinoma of the
bronchus and patients who had a radical mastectomy performed for carcinoma ofTHE BONE MARROW IN MALIGNANT DISEASE
the breast. The exact selection ofpatients is considered in detail under the results
but these groups included all types ofmalignant disease at all stages. The investi-
gation was commenced in December, 1951, and all sternal punctures reported
here were performed before August, 1955.
The clinical examination of the patient was made by the staff of the Radio-
therapeutic Department and the authors were only informed of these clinical
details after the marrow had been assessed. Thus it was hoped that bias in
interpretation would be avoided. The follow up ofthe patients was done by seeing
the patients personally or where they lived at a distance from Cambridge, studying
the clinical records collected at the outside clinics attended by the radiotherapists.
The follow up has been continued until March, 1956, and has varied from six
months to just over four years.
ThemarrowaspirationswereperformedwithaTurkelneedleandthemanubrium
sterni was the site routinely chosen. Occasionally the marrow was aspirated from
the body of the sternum when the presence of deformity or a previous fatty
aspiration from the manubrium rendered it advisable. About 0.25 ml. of marrow
fluid was withdrawn and after taking a few drops of the aspirate for 6-8 smears,
the remainder was put into a Wintrobe's oxalate tube. From this tube any bone
marrow flecks visible were picked by means of a fine wire loop. The fleck was
spread on a glass slide. Both the film and fleck preparations were stained with
Leishman stain. A total cell count was also performed on the oxalated marrow.
The film and fleck preparations were then initially examined individually
and independently by two ofthe authors. A differential count ofat least 200 cells
was performed and in addition preparations thoroughly and systematically
searched, the following points being noted:
1. Cellularity.
This was noted according to impression as low, normal orhypercellular.
The classification corresponded almost exactly with the total counts
recorded as under 20,000; 20,000-100,000 and over 100,000 respectively.
2. Plasma cell content.
This was assessed.on the general appearance including the finding of
plasma cell nests, and on the differential marrow count.
3. The presence of abnormal cells in the marrow sample.
As the films were examined microscopically cells that are not usually
seen in marrow aspiration were encountered. These were then examined
in further detail and an attempt made to define their exact nature. Some
undoubtedly represented tumour cells while some were considered to be
osteoclasts, osteoblasts or nests of degenerating plasma cells. The distin-
guishing features are considered later.
The two individual assessments were made entirely independently and the
results then compared andthe marrow classifiedinto one ofthree groups namely:-
1. Positive.-The marrow contained cells considered to be definitely malignant.
2. Suspicious.-There was a definite plasmacytosis in the absence ofany other
cause with usually a hyperplasia of the other marrow elements. A few cases
were included in this classification in which atypical cells were found but because
they occurred in small numbers or singly could not be definitely classed as malig-
nant cells. Such marrows, however, usually showed a plasmacytosis and would
be classified as suspicious on that criteria as well.
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3. Negative.-No abnormal cells and no abnormal bone marrow reactions
were detected.
Only rarely has disagreement existed between the authors as to the classifica-
tion and under these circumstances a compromise was reached as to the one
recorded or if there was considerable doubt a repeat marrow examination has
been made.
Marrow examinations have been made on 601 patients suffering from malignant
disease. In addition to this, during this same time over 200 patients with diseases
of the reticulo-endothelial system (e.g. leukaemia, Hodgkin's disease) had a
marrow examination, but these patients are omitted entirely from discussion
in this paper since marrow involvement may occur early in these diseases and the
changes are already well recognised. Sarcomata were also excluded as the grade
ofmalignancyisdifficulttointerpret. Inaddition, asacontrol,wehavere-examined
over 1,000 marrow punctures made during the past few years on patients with
anaemia, on normal and abnormal infants (Gairdner, Marks and Roscoe, 1952)
and many other generalised diseases including ankylosing spondylitis (Pillers and
Marks, 1956). Among this control series no marrow which we would classify as
positive was found.
Clinical assessment of the patient
The clinical stage of advancement of the malignant disease was recorded as
early, intermediate or advanced according to the following criteria :
1. Early.-Those patients with only apparently localised disease and with no
detecable spread beyondtheregionallymphnodes. Thisincludes cases with mobile
enlarged lymph nodes but excludes fixed nodes.
2. Intermediate.-Those patients showing clinical evidence of spread beyond
(1) but no clinical evidence of involvement of the liver or clinical or radiological
evidence of bone metastases.
3. Advanced.-Those patients in whom there is radiological evidence or
clinical evidence of widespread metastases particularly in the bones or liver.
In addition to this assessment of the stage of advancement of the malignant
disease patients were given a general medical examination. Most of the patients
investigated were in good general health and in this present investigation much
effort has been made to concentrate on the early cases rather merely examining
patients already showing obvious evidence of widespread malignant disease.
EXPLANATION OF PLATES.
FIa. la.-Low power ( X 140) and high power (X 700) view of cluster of malignant cells.
Note :-1. Grouped cells with syncytium (a) of lacy cytoplasm and indistinct borders.
2. Nuclei large, hyperchromatic, stippled chromatin and nucleoli (b).
FIa. lb.-Group of osteoblasts (x 550). Note:-1. Eccentric nuclei. 2. Indistinct marginofcytoplasm (brilliant blue). 3. Archo-
plasm (a) may be at distance from nucleus. 4. Nucleoli (b).
FIa. lc.-Osteoclast (x 550).
Note :-1. Syncytial granulated cytoplasm (a). 2. Large round disconnected nuclei
with stippled chromatin. 3. Nucleoli (b).
FIa. ld.-Plasma cell "group" ( X 550).
Note:-1. Eccentric nucleus with dense chromatin. 2. Cytoplasm (dense blue) shows
clear margin. 3. Perinuclear archoplasm (a).
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The clinical staging we have used corresponds in the case of carcinoma of the
cervix uteri to the following Stockholm staging. (Stockholm Report, 1951).
Early - I + II
Intermediate III
Advanced - IV
The survival times were calculated from date of marrow examination to the
present time or to the date of death.
RESULTS
The present series may be divided into five main groups for consideration of
results and the discussion, namely carcinomata of the breast, bronchus, cervix
and ovary and a heterogenous group in which the individual types of tumours
were too few to warrant separate detailed consideration. Details of the number
and type of the cases that have been punctured and a summary of the marrow
results are shown in Table I.
TABLE I.-Details of the 8ite of the primary tumour and the marrow results
Marrow results.
Site of No. ofpatients ·
neoplasm. studied. Positive. Suspicious. Negative.
Breast . . . . . 190 . 12 42 136
Lung . . . . . 125 . 14 47 64
Cervix . . . . . 61 . 1 23 37
Ovary . . . . . 30 . 2 14 14
Upper resp. tract . . . 29 . 0 9 20
Alimentary canal . . . 28 . 1 11 16
Male genital tract . . . 20 . 0 2 18
Female genital tract . . 15 . 0 5 10
Urinary tract . . . . 17 . 0 7 10
Skin . . . . . 20 . 1 4 15
Melanoma (all sites). . . 10 0 2 8
Endocrine system . . . 11 . 0 4 7
Miscellaneous . . . . 19 . 0 3 16
Carcinomatosis . . 26 . 6 7 13
(unknown primary)
Totals . . . . 601 . 37 180 384
Results in patients wth carcinoma of the breast
Excluding male patients and patients with a second primary neoplasm 190
patients with primary carcinoma ofthe breast have been examined.
The marrow results and survival times to date in this series are given in Fig. 2.
The survival times calculated to date for these patients show no obvious
difference between the negative, suspicious or positive marrows although such
results cannot be of great value at present in assessing the prognosis since 129
ofthe patients are still alive. Thefigures, however, maybe considered in adifferent
way, ifevidence ofprogression ofdisease is taken as a criteria in eachofthe marrow
groups.
Among the 136 patients with negative marrow 54 patients (40 per cent) are
either dead or show evidence of disease progression. In the suspicious marrow
group 26 patients (approximately 62 per cent) have progressed since the marrow462 E. M. K. PILLERS, J. MARKS AND J. S. MITCHELL
examination was made, while in the 12 patients with positive marrows 9 (75 per
cent) ofthe patients show progression ofthe disease and 7 ofthese are dead.
Thus the results suggest that a further follow-up may result in a gradual
difference in prognosis appearing between the three groups of patients since,
in the negative group, there are far more patients who are now clinically and
radiologically normal.
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FIG. 2.-Results in 190 patients with carcinoma of the breast.
Results.in patients with carcinoma of the bronchus
One hundred and twenty-five patients suffering from primary carcinoma of
the bronchus have been examined. The diagnosis of carcinoma of the bronchus
has been confirmed in these patients by thoracotomy, by biopsy, by broncho-
scopy or in a very few cases only by the finding of malignant cells in pleural
effusion or sputum.
The marrow results in this series and the survival times are given in Fig. 3.
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FIG. 3.-Results in 125 patients with carcinoma of the bronchus.
The division of these patients into stages is much more difficult than with
other carcinomata. Early patients are those who show no extrathoracic spread
and no involvement ofthe ribs and who onbronchoscopic evidence were considered
suitable for surgery. Manyofthese patients subsequently underwent thoracotomy.
The advanced cases were those who were, at the time of marrow examination,
known to have liver or bone involvement, while the intermediate group showedTHE BONE MARROW IN MALIGNANT DISEASE 463
some extrathoracic spread but no clinical or radiological evidence of spread to
the liver or bones.
The average survival times for the patients with negative marrows was seven
months, for the suspicious marrows six months, and for the positive marrows
five months. Since only nine of the patients are still alive with no evidence of
spread of the disease these survival times are not likely to be greatly modified
except for a possible slight prolongation of the group with negative marrows
relative to the others.
Results in patients with carcinoma of the cervix uteri
The results of the marrow findings and the survival times for 61 patients
with carcinoma of the cervix uteri who have been investigated are given in Fig.
4. Patients with negative marrow findings had an average survival time ofsixteen
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FIG. 4.-Results in 61 patients with carcinoma of the cervix.
months, those with suspicious marrows an average of eight months, while the
patient with a positive marrow, even though classed as an intermediate case
clinically died two months after the finding of a positive marrow. There is a
statistically significant difference between the survivals in the negative and
suspicious group. (Students t-test - n = 32; t = 3.36; P _ 0'002; inclusion
of the one positive marrow makes no difference to this significance.)
Among the patients with negative marrows 23 (63 per cent) are alive with no
evidence of spread, while in the suspicious group only 3 (13 per cent) are still
alive and well. Thus the difference between the negative and suspicious marrows
should become considerably greater with a longer follow up.
The only positive marrow in this series showed no radiological evidence of
spread and was, at the time of the marrow examination, in fairly good general
condition. She died however two months later with clinical evidence of wide-
spread disease.
Results in patients with tumours of the ovary
Thirty patients with ovarian tumours have been studied and the results are
shown in Fig. 5. Classification into clinical stages has been done entirely on the
findings at operation, early cases showed no evidence of spread outside the ovary
and were operable. The intermediate group showed local extension and wereE. M. K. PILLERS, J. MARKS AND J. S. MITCHELL
inoperable as far as radical surgery was concerned, while advanced cases showed
liver and bone secondaries.
The average survival time in the patients with negative marrows was sixteen
months, with suspicious marrows eleven months, and in two patients with positive
marrows two months.
Both the positive marrow patients are dead, and only 2 (14 per cent) of the
patients with suspicious marrows showed no evidence offurther spread ofdisease.
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FIa. 5.-Results in 30 patients with ovarian tumours.
Among the patients with negative marrows 4 (28 per cent) are still alive and well.
Thus inthis group too, difference in survival times is likely to become more marked
relative to the marrow classification rather than less marked. (Students t for all
negative against positive and suspicious n = 28; t 2-32; P 0-27 and is
significant at the 5 per cent level.)
Results in a group ofpatients with carcinoma of various sites and types
One hundred and ninety-five patients suffering from primary neoplasms of
sites other than those already mentioned have been investigated. The diagnosis
and the marrow findings are given in Table I. In a mixed group of this sort with
diseases havingvaryingnaturalhistories followup datawouldbevalueless. Positive
marrowaspirations werefoundonlyin two patients inwhomthesiteofthe primary
growth was known (stomach and skin), but six patients with carcinomatosis
with an unknown primary tumour have yielded a positive aspiration. Suspicious
marrows were found only in 3 patients.
The marrows eosinophil count in patients with malignant disease
A total eosinophil percentage in the marrow has been calculated for each
puncture. Table II gives details of the patients of the four main groups who
showed a marrow eosinophilia (over 7-5 per cent). Eighteen out of 406 patients
show a marrow eosinophilia but there is no apparent correlation in the clinical
status or the follow up of these patients.
No eosinophilia was found among the patients with positive marrows and
the incidence ofeosinophilia among the patients with suspicious marrows was not
more than would be expected by chance ifthe frequency ofeach ofthese conditions
is considered.
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TABLE II.-Clinical staging, marrow result, and actual and calculated
follow-up on patients showing a marrow eosinophilia
Clinical Marrow Expected
Diagnosis. Case No. status. result. Follow-up. follow-up.
Carcinoma, breast . 33 . E . - ve . 33 spread 21
77 . E . - ve . 7 dead* . 21
79 . A sus . 7 dead . 5
Carcinoma, bronchus. 2 I . sus . 3 dead* . 5
10 . I . sus . 10 dead . 5
11 . E . sus . 11 dead . 9
26 . I . -ve . 2 dead* . 7
28 . E . sus . 4 dead* . 9
60 . I . -ve . 2 dead* . 7
92 . I . -ve . 11 dead 7
Carcinoma, cervix . 7 . I . -ve . 38 a. & w. . 12
17 . E -ve . 29 ,,,,,, 20
20 . E . sus . 3 dead* . 11
33 . I . -ve . 20 a. &w. 12
40 . I . sus . 2 dead* . 8
Ovarian tumours . 1 . I . su . 12 dead . 12
4 . I -ve . 18 dead . 14
12 . I . - ve . 12 dead* . 14
*Patient with a poorer prognosis than expected.
DISCUSSION
The identification ofmalignant cells in the marrow
Theidentification ofmalignant cells inthe marrowis often a matter ofconsider-
able difficulty, and requires knowledge ofthe normal marrow cells under a variety
of conditions.
Since the primary tumours differ so much in their morphology it is only to
be expected that the nodules in the marrow would show a similar considerable
variation in cytology. Thus it is only possible to give broad generalisations of
the distinguishing features. These features can be summarised as
1. The general sturcture and staining qualities of the cells are at variance
with those ofthe normal cells ofthe marrow, i.e. the cells are foreign to the normal
marrow elements.
2. The cells are usually arranged in a group of cluster and have a tendencyto
form a syncytium.
3. There is a great variation in the cell size, but the cells are usually large-10
to 30/t in diameter.
4. The cytoplasm may be abundant or scanty. When abundant it is often
fragile, lacy or vacuolated with indistinct borders and may even be absent. It may
be slightly or deeply basophilic in staining.
5. The nucleus is usually large and hyperchromatic with stippled nuclear
chromatin.
6. The nucleoli are usually prominent, usually 1-3 in number and may be
disproportionately large in relation to the nucleus. As described by Stoger (1941)
the smaller cells may have no nucleoli, but the finding of these small malignant
cells with no nucleoli is extremely rare and the authors feel that considerable
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care should be exercised in identifying these as true tumour cells. The majority
of such cells are probably plasma cells.
7. Many other workers describe mitotic figures as being numerous, but in our
experience they appear to be numerous only in those cases in which the marrow is
entirely replaced by sheets of malignant cells.
At the present stage of the investigation it is not considered possible to deter-
mine the site of the primary tumour from the cytological characteristics of the
cells found at bone marrow puncture. Rohr and Hegglin (1936) suggested that
small cells occurring in groups might indicate a secondary from a carcinoma of
the bronchus while large cells sometimes occurring singly could suggest the
prostate orstomach as primary. Amy and Jaimet (1953) reported similarfindings.
Rohr's figures are however on the basis of 7 positive aspirations in carcinoma of
the bronchus and in intestinal carcinoma. In the present work we have been
unable to confirm their conclusions in carcinoma of the bronchus for out of the
14 positive aspirations that we report only 2 showed clusters of small cells. There
are certain other cells which may easily be confused with malignant cells in the
marrow. Some of these have undoubtedly confused other authors to judge from
the photomicrographs that they reproduce and have caused us considerable
worry at times in arriving at a firm conclusion.
Fig. la shows a typical cluster of malignant cells.
Osteoblasts and osteoclasts
These cells would seem to produce more confusion than the rest. They were
described by Esser in 1945 and were stated by her to occur much more commonly
in children's marrows than adult. Although these cells are normal in bone biopsies
they are seen only rarely in aspiration samples of marrow. They may occur either
singly or more commonly in our experience in small clusters.
The osteoblasts closely resemble plasma cells with their eccentric nuclei and
brilliant blue cytoplasm, but are much larger in size-20-30,. They'may show
azurophilic granules, and the margin is usually indistinct. The pale round area
of archoplasm is some distance from the nucleus whereas it is adjacent to the
nucleus in plasma cells. There are usually one or two nucleoli.
The osteoclasts are multinucleate cellswith big round disconnected nuclei, and
granular cytoplasm which shows some resemblance to the cytoplasm of mega-
karyocytes.
These cells have been stated (Tischendorf and Heckner, 1950) to be present in
the marrow only under certain pathological conditions in adults but we have seen
them both singly and in clumps not only in carcinoma, but also in Hodgkin's
disease, spondylitis andothernon-malignant conditions. Asfaraswe candetermine
they have no especial significance relative to the conditions, but may provide
diagnostic difficulty.
Fig. lb and lc show typical osteoblasts and osteoclasts in sternal marrow
aspiration.
Plasma cell nests and degenerating plasma cells
Degenerating plasma cells may occur either singly or in clumps, and are larger
than most other normal marrow cells. The nucleus may show pyknosis with
early fragmentation and occasionally an intra-nuclear vacuole which may give the
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appearance of a false nucleolus. The cytoplasm is plentiful and usually faintly
staining, while the cell outline is often indistinct. These cells are described by
Hayhoe and Smith (1951) and occur in many conditions other than malignant
disease.
Plasma cells commonly occur singly in the marrow but where there is a plasma-
cytosis they may also be found in nests. Frequently these nests contain a multi-
nucleate plasma cell in addition to several with single nuclei, and the first impres-
sion is often of a syncytium. The dense blue cytoplasm, the dense chromatin in
the nucleus with no nucleoli and the perinuclear archoplasm, distinguish these
nests from a cluster of malignant cells.
A typical plasma cell group is shown in Fig. ld.
The incidence ofpositive aspirations
Among the present series there has been an incidence of 6.2 per cent positive
aspirations (37 out of 601 patients) or 7 percent in thefourmaingroups considered
(29 out of 406 patients). This at first sight compares very unfavourably with the
results of previous workers (Table III), in patients with similar diagnoses. Thus
overall they found approximately 32 per cent of the patients hadpositivemarrow
findings. This is to a very considerable extent due to the different selection of
patients. Among the patients with positive aspirations in the four main groups of
this present series 18 or 62 per cent were found in patients with no radiological
evidence of spread of disease. In the patients investigated by other workers
onthe other hand only 10 per cent of the positive aspirations were found among
patients with no radiological evidence of spread. Previous workers have in fact
almost entirely confined their attentions to patients with advanced disease.
Thepresent series on the otherhand deliberately concentrated on theless advanced
cases.
TABLE III.-Comparison of the positive marrow aspirations in the present series
with those reported by previous workers in patients with primary tumours of
similar sites
Author. Breast. Lung. Cervix. Ovary. Total.
Vogel, Erf and Rosenthal 2 (2) . 0 (5) . 0 (1) . . 2 (8)
1937
Kryeberg and Poppe, 1940 3 (26) . 0 (1) . 0 (1) . - . 3 (28)
Selberg, 1942 . . . 3 (6) . 4 (12) * 7 (18)
Franke, 1942 . . 2 (11) . 5 (22) . 2 (5) . 0 (2) 9 (40)
Gormsen, 1942 . 19 (98) . 2 (7) . - . - . 21 (105) Weisberger and Heinle, 2 (10) . 2 (8) . 0 (2) - 4 (20)
1948
Lanier, 1949 . . 2 (5) . 0 (2) . 0 (2) . - . 2 (9)
Jonsson and Rundles, 1951 8 (14) . 6 (14) . - . - . 14 (28)
Rubinstein and Smellin, 21 (35) . 4 (10) . 25 (45)
1951
Rubinstein and Smellin, 20 (32) . 5 (10) . 25 (47)
1952
Total . . . 82 (239) . 28 (96) . 2 (11) . 0 (2) . 112 (348)
Present series . . . 12 (190) 14 (125) 1 (61) 2 (30) 29 (406)
4* 12* 1* 1* 18*
* Denotes the number of patients showing positive marrow aspiration andc. no X-ray evidence
of bone metastases.
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Sternal aspiration as a methodfor the detection of tumour cells
In order to find tumour cells in the maximum number of patients one should
puncture the bone that shows radiological evidence of spread. We have, on occa-
sions, taken radiographs of various bones including the sternum to find a suitable
site for puncture but such radiographic examinations are costly and time con-
suming and are not feasible in many units undertakinglarge numbers of routine
examinations. In addition it has already been shown that positive aspirations
may be found where there is no radiological evidence of disease.
Bone marrow aspiration can be performed in the sternum, the iliac crest and
the vertebrae. There is evidence both from autopsy examinations (Selberg, 1942)
and from patients with multiple examinations (Clifton, Philip and Fowler, 1952)
that sternal marrow aspiration yields a slightly higher number of positive results
than either iliac crest or vertebral spine examinations where previousradiographic
investigation is not undertaken. The finding ofcells in the sternal marrow cannot
be ascribed to direct extension in carcinoma ofthe breast and bronchus.
Thus where it is impossible to determine the site ofsecondaries byradiographic
examination or where there is no evidence of spread, examination of the sternum
is probably the method of choice and is the one that we have adopted.
The significance of a marrow plasmacytosis
An increase of plasma cells in the marrow has been reported in a variety of
conditions both physiological and pathological. Among these may be mentioned
rheumatoid arthritis (Hayhoe and Smith, 1951). chronic infections, measles,
cirrhosis, and Hodgkin's disease; for review of cause of marrow plasmacytosis
vide Fadem and McBirnie (1950).
Such an increase has however been reported to occur in malignant disease and
in such cases may indicate the presence of a generalised spread. Stoger (1941)
examined the marrows of 110 patients with malignant disease and found that in
84 per cent ofhis tumour free biopsies a plasma cell reaction from 1-1-16 per cent
plasma cells was present. Morel (1947) suggested that a plasmacytosis greater
than 4 per cent suggested the presence of a widespread neoplasm, while Lanier
(1949) in her series of 32 cases found numerous clumps ofplasma cells. Amy and
Jaimet (1953) similarly found an increase of plasma cells from 2 to 13 per cent.
In view of the numerous conditions that can give rise to a plasmacytosis this
reaction caninnowaybe considered specificformalignancy. Such areactionshould
be considered as evidence ofsome generalised body disturbance and a cause sought.
In the absence of other cause in a patient with an already proven malignancy it
is possible that the presence ofthis neoplasm may be the exciting factor.
In the present series those patients with a plasmacytosis have been fully
investigated in an attempt to discover any other possible cause. When none has
been found they have been included in the classification of patients with a
suspicious marrow. The significance of this plasmacytosis in relation to the prog-
nosis of patients with malignant disease is considered in a subsequent section.
The significance of a bone marrow eosinophilia
A few previous workers have noted an eosinophilia in the bone marrow of
patients with neoplastic disease. Morel (1947) felt an increase of eosinophils of
over 5 per cent was significant of neoplasm where no other cause could be found.
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Lanier (1949) found an increase in 44 per cent ofher patients but cited Nordensen
(1935) as stating that it was an infrequent occurrence in his series of 17 patients.
In the present series 18 out ofthe 406 patients analysed showed aneosinophilia
(over 7.5 per cent mature eosinophil and precursors). There is at present no
apparent correlation between the clinical status and the follow up ofthesepatients.
No eosinophilia was detected in the 37 patients with positive bone marrow
aspirations. Eight of the 18 patients with eosinophilia were classified by other
criteria as suspicious.
Among the patients with a marrow classification of suspicious and an eosino-
philia 4 (50 per cent) had a prognosis poorer than the average expected survival
time, among those with eosinophilia and negative marrows 4 (40 per cent) had a
prognosis poorer than the average expected survival time.
Thus at the present time there is little evidence that eosinophilia can be con-
sidered to signify poorprognosis in malignant disease.
The relationship between the marrow classification and the clinicalfollow up
The four main groups considered have an entirely different natural history
and therefore the results of the follow up study must be considered separately
for each type of primary neoplasm.
In carcinoma of the bronchus patients showing a positive marrow have an
average survival time of five months, those with a suspicious marrow six months
and those with a negative marrow seven months with a greater percentage of
the patients still alive and well who had a negative marrow examination. Thus the
prognosis when a positive marrow was found seems to be rather shorter than with
either a suspicious or a negative marrow while a suspicious marrow gives a slightly
poorer prognosis than the negative marrow. Differences in the average survival
times however are short.
In carcinoma of the cervix average survival times are significantly longer with
a negative marrow than with either a suspicious marrow or a positive marrow, and
the patient with a positive marrow showed an extremely short survivaltime. These
differences are likely to become more pronounced for the majority of the patients
with a negative marrow are still alive and well.
In ovarian tumours two patients with a positive marrow showed a very short
survival time while those patients who had a negative marrow had a slightly better
prognosis than those with a suspicious marrow.
In carcinoma of the breast no differences can be found so far in the series
examined between the average survival times ofpatients with negative, suspicious
and positive marrows but in carcinoma of the breast the overall survival time is
long and the majority of patients are still alive and well. If evidence of spread
of the disease is considered, however, more patients with positive and suspicious
marrows show evidence of spread. A longer follow up however will be necessary
before clear-cut results can be found for carcinoma ofthe breast.
Considering each of these groups there is evidence to suggest that correlation
exists between the marrow findings and the clinical follow up. Marrow puncture
can give evidence of spread ofthe disease but although this would on the average
signify a poor prognosis it does not of course necessarily signify a very early death
and should be used as a further indication of general spread.
The finding of a suspicious marrow on the other hand cannot be considered
as pathognomonic of malignant spread for many other conditions can give these
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changes. A suspicious marrow however must not be dismissed until a cause has
been found. Should no other cause be determined, there is evidence from this
present study to suggest that tumour spread may exist with a consequent poor
prognosis to the patient.
CONCLUSIONS
The value of sternal puncture in the treatment of carcinona
The present results in this series suggest that the following firm conclusions
may be drawn.
1. Sternal puncture has a definite value in assessing the prognosis in both
carcinoma of the cervix and carcinoma of the ovary but has little value in deter-
mining the prognosis in carcinoma of the bronchus. In carcinoma of the breast
the natural history of the disease is so long that no definite conclusions can be
drawn at present as to the value of sternal puncture in assessing prognosis.
2. Sternal puncture has a definite place in assessing thetypeoftreatment that
should be used.
(a). Carcinoma of the bronchus.
Wherethere is evidence ofspread as determined by apositivemarrowaspiration
major surgery should be avoided except as a purely palliative measure.
(b) Carcinoma ofthe ovary.
Here a decision must be made between palliative and radical X-ray therapy.
With a negative marrow examination there is strong evidence from this series
thatno spreadexists and under these circumstances radical therapy in the maxi-
mum tolerated dose is indicated.
(c) Carcinoma of the cervix.
Those patients who show a suspicious or positive marrow and fail to respond
locally to primary radiotherapy have not benefited greatly from Wertheim's
radical abdominal hysterectomy.
3. It is possible by sternal marrow examination to detect spread of tumour
earlier than with X-rays but the method is extremely time-consuming (about
three hours per patient) and requires considerable experience of normal and
abnormalbonemarrows. It consequently willprobably have noplacein theroutine
radiotherapeutic department.
4. Sternal marrow may provide cytological material for diagnosis bft at the
present moment only ofthe presence of malignancy. With further experience the
site of the primary tumour may possibly be diagnosed.
5. The finding ofa suspicious marrow should be used as a guide to the presence
of organic disease, and a suspicious marrow should never be dismissed until the
cause is determined.
SUMMARY
The results are reported on sternal marrow examination of 601 patients
suffering from carcinoma. The majority of these patients were clinically well
and at an early stage ofthe disease Four hundred and six patients with carcinoma
of the breast, bronchus, cervix uteri and ovary are considered in detail.
The follow-up has varied from six months to over 4 years.
Thirty-seven patients showed tumour cells in the marrow, while 180 showed
amarrowplasmacytosis. Evidenceispresentedthatprognosis isworst withtumour
470THE BONE MARROW IN MALIGNANT DISEASE 471
cells in the marrow, but that in carcinoma ofthe bronchus, cervix uteri and ovary,
a marrow plasmacytosis is associated with a poorer average survival than patients
showing no marrow plasmacytosis.
It is suggested that sternal marrow examination has a place in assessing the
type oftreatment andinproviding cytological materialfordiagnosis ofmalignancy.
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